Reply  by Goldbarg, Seth H. et al.
Reply
We appreciate the insights that Dr. Merryman offers regarding
degenerative aortic valve disease (DAVD) and our recent article
(1). He emphasizes the point that the aortic valve interstitium
plays a paramount role in the process of valve degeneration. The
authors agree that the interstitium, along with the endothelium,
generates an inflammatory milieu that promotes DAVD, and that
structural changes in the interstitium and endothelium are inherent
to the disease process. We attempted to discuss this in our review
but perhaps should have further emphasized the importance of the
interstitium to this process.
We agree with Dr. Merryman that matrix remodeling and
degradation may result from direct effects on the interstitium (2,3).
The effects of cytokines within the interstitium include the
upregulation of matrix metalloproteinase (MMP), which causes
valvular remodeling by degrading the extracellular matrix (4). As
we state in our article, MMP seems to regulate valve plasticity, but
its overexpression in DAVD leads to elastin degradation in the
interstitium, which may contribute to adverse remodeling (5,6).
We highlight the transformation of myofibroblasts into an osteo-
genic phenotype under the influence of cytokines, which alter
expression of MMP and bone morphogenic protein (BMP) (7,8).
Aortic valve remodeling is strongly linked to altered expression and
cytokine production in the myofibroblasts of the interstitium.
In our review we discuss the hemodynamic and mechanical
forces that affect the aortic side of the valve and the structural
remodeling of the endothelium on that surface. The cascade of
downstream effects initiated by endothelial disruption leads to the
changes described above. As Dr. Merryman postulates, there may
be further effects caused by altered stress transfer from variably
oriented collagen fibers in the interstitium of aging valves. We
agree that this process may contribute to the pathological changes
described in DAVD. However, Dr. Merryman’s statement that
nearly all DAVD pathology originates in the fibrosa may exclude
other important processes contributing to this pathology. In
addition, although Dr. Merryman has shown that transforming
growth factor 1 alters smooth muscle alpha-actin and type I
collagen C-terminal propeptide in an in vitro model, the notion
that DAVD in vivo is largely predicated on transforming growth
factor 1 activation may be a generalization (9).
In conclusion, we agree that the interstitium and the myofibro-
blasts therein play a critical role in the pathogenesis of DAVD.
Stress transfer within the interstitium likely contributes to matrix
remodeling and cytokine activation, but further studies are needed
to confirm current studies and determine the relative importance of
this pathway.
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Vascular Closure Devices:
Begin With the End in Mind
In their review of the history and future of vascular closure devices,
Dauerman et al. (1) discuss a variety of factors that affect vascular
complication rates. They note that there are cautions and contrain-
dications regarding the use of vascular closure devices and indicate
that post-procedure femoral angiography is a “significant advance” in
reducing complications, because it identifies the 13% of patients with
nonfemoral sheath insertion and also those with insertion above the
inferior epigastric artery.
We would liken this practice to secondary prevention. As
important as that is, most of us would like to achieve primary
prevention and prevent incorrect sheath location. To achieve that,
it has been widely recommended that pre-procedure fluoroscopy of
the femoral head would help to reduce inaccurate sheath insertion
and lower complication rates.
Unfortunately, the authors do not even mention the most accurate
method of sheath insertion: the use of needle-guided vascular ultra-
sound imaging. Invasive and interventional cardiologists relying on
surface or fluoroscopic landmarks depend upon normal anatomy and
palpation to guide their punctures. In percutaneous coronary inter-
vention procedures this is uncomplicated about 98% of the time, as
noted in the article and by the NNECVDG (Northern New England
Cardiovascular Disease Study Group) Registry.
In our experience, routine ultrasound use can substantially lower
this small but costly complication rate. It has long been advocated
in the anesthesia community for safe and successful central venous
access. Prospective data to prove this claim are, unfortunately, not
yet available for femoral access.
In the cardiac catheterization laboratory, ultrasound is some-
times used for the “difficult patient,” relegating it to a situation that
disrupts the flow of the procedure and may be frustrating, since
rare use on the most difficult patients makes for a long learning
curve. Routine ultrasound use, however, can be done very quickly
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